ESMO 2021 - Results from #60

Viewing 61-80 of 137 articles

ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial (Meeturo 2)

ESMO 2021: Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of Expanded Cohort 6 of the COSMIC-021 Study

ESMO 2021: PRINCE: Interim Analysis of the Phase Ib Study of 177Lu-PSMA-617 in Combination With Pembrolizumab for Metastatic Castration Resistant Prostate Cancer

ESMO 2021: Cabozantinib in Combination with Atezolizumab in Patients with mCRPC: Results of Expanded Cohort 6 of the COSMIC-021 Study: Invited Discussant

ESMO 2021: Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + ADT in Men With mHSPC

ESMO 2021: Cabozantinib-Nivolumab Versus Nivolumab-Cabozantinib in Patients With Metastatic Clear Cell RCC Following One Prior VEGFR TKI: The CABIR Multicenter Matching-Adjusted Study

ESMO 2021: Real-World Utilization of Advanced Therapies by Metastatic Site and Age Among Patients With mCSPC: A Medicare Database Analysis

ESMO 2021: Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma: Outcomes in Subgroups and Toxicity Update

ESMO 2021: Estimation of Overall Survival With Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study

ESMO 2021: Randomized, Open-Label, 3-Arm Phase 3 Study Comparing MK-1308A + Lenvatinib and Pembrolizumab + Belzutifan + Lenvatinib versus Pembrolizumab + Lenvatinib as First-line Treatment for Advanced Clear Cell RCC

ESMO 2021: Pembrolizumab Plus Olaparib in Patients with Docetaxel-Pretreated mCRPC: Update of KEYNOTE-365 Cohort A with a Minimum of 11 Months of Follow-Up for all Patients

ESMO 2021: Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial Identify Therapy Resistance

ESMO 2021: Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer Patients in the US

ESMO 2021: Conditional Survival and 5-Year Follow-Up in CheckMate 214: First-Line Nivolumab + Ipilimumab Versus Sunitinib in Advanced RCC

ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and SBRT to the Prostate in Men with Newly Diagnosed mHSPC

ESMO 2021: A Discussion on the Results of the GETUG/AFU VESPER V05 Phase III Trial and on Pembrolizumab in Combination with sEphB4-HSA (B4) in a Phase II Trial for Previously Treated Metastatic Urothelial Carcinoma

ESMO 2021: Phase II Trial of Pembrolizumab (P) in Combination with sEphB4-HSA (B4) in Previously Treated Metastatic Urothelial Carcinoma (mUC)

ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin As Perioperative Chemotherapy for Patients With MIBC

ESMO 2021: Apalutamide for Advanced Prostate Cancer in Older Patients: Combined Analysis of TITAN & SPARTAN

ESMO 2021: Pembrolizumab Monotherapy for Docetaxel-Pretreated mCRPC: Updated Analyses with 4 Years of Follow-up from Cohorts 1-3 of the KEYNOTE-199 Study

1
2
3
4
5
6
7